Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18822564 | Dry Powdered Formulations | September 2024 | August 2025 | Abandon | 11 | 1 | 1 | No | No |
| 18639137 | ADHESIVE MEDICAL PRODUCTS AND METHODS FOR TREATING GASTROINTESTINAL LESIONS | April 2024 | March 2026 | Abandon | 23 | 2 | 0 | Yes | No |
| 18410155 | EVA SEGMENTED INTRAVAGINAL RINGS CONTAINING PROGESTERONE | January 2024 | December 2025 | Abandon | 24 | 2 | 0 | No | No |
| 18515201 | METHOD FOR PREPARING POLY(THIOCTIC ACID)-COPPER COATING ON SURFACE OF CARDIOVASCULAR STENT MATERIAL | November 2023 | November 2025 | Allow | 23 | 0 | 0 | No | No |
| 18506493 | SUBSTITUTED PHENYL BORONIC ACID CONTAINING POLYMERS AND METHODS OF USE | November 2023 | June 2024 | Allow | 7 | 1 | 0 | No | No |
| 18483098 | FREEZE-DRIED ARIPIPRAZOLE FORMULATION | October 2023 | January 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18477212 | METHOD FOR SKIN PROTECTION BY USING A ZnO/NSP COMPOSITE | September 2023 | October 2025 | Allow | 25 | 0 | 0 | No | No |
| 18364862 | COMPRESSED NICOTINE LOZENGE | August 2023 | August 2025 | Allow | 25 | 2 | 0 | Yes | No |
| 18345770 | NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY | June 2023 | March 2025 | Allow | 20 | 1 | 0 | No | No |
| 18339800 | COMPOSITIONS FOR COATING EDIBLE SUBSTRATES AND METHODS OF MAKING AND USING THE SAME | June 2023 | June 2025 | Abandon | 24 | 2 | 0 | No | No |
| 18338382 | RAPAMYCIN FOR INCREASED MILK PRODUCTION | June 2023 | February 2026 | Abandon | 32 | 1 | 0 | No | No |
| 18329422 | COMPOUND, PRODUCTION METHOD THEREFOR, AND HYDROGEN SUPPLY METHOD | June 2023 | January 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18254286 | METHOD FOR PREPARATION OF EFFERVESCENT GRANULES | May 2023 | September 2024 | Allow | 16 | 2 | 0 | No | No |
| 18253766 | CONTROLLED ENTRAPMENT AND RELEASE OF MOLECULAR CARGO | May 2023 | June 2024 | Allow | 13 | 1 | 1 | Yes | No |
| 18251744 | METHOD FOR PREPARING BIODEGRADABLE MICROCAPSULES AND MICROCAPSULES THUS OBTAINED | May 2023 | January 2026 | Allow | 33 | 0 | 1 | No | No |
| 18043452 | Zwitterionic Hydrogels and Methods of Making and Using Same for Protein Therapy | February 2023 | January 2026 | Abandon | 35 | 1 | 0 | No | No |
| 18108576 | METHOD OF MANUFACTURING SPRAY-DRIED POWDERS | February 2023 | May 2025 | Allow | 27 | 1 | 1 | No | No |
| 18151604 | SUBSTITUTED PHENYL BORONIC ACID CONTAINING POLYMERS AND METHODS OF USE | January 2023 | April 2024 | Abandon | 15 | 0 | 0 | No | No |
| 18147254 | HYDROGEN SUPPLY MATERIAL AND PRODUCTION METHOD THEREFOR, AND HYDROGEN SUPPLY METHOD | December 2022 | January 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18009373 | COMPOSITION COMPRISING PENTAPEPTIDE AS ACTIVE INGREDIENT | December 2022 | October 2025 | Allow | 34 | 1 | 0 | No | No |
| 18059475 | INSECT AND NON-INSECT ARTHROPOD PEST REPELLENT COMPOSITIONS AND METHODS | November 2022 | February 2025 | Abandon | 26 | 1 | 1 | No | No |
| 17930261 | SIMETHICONE CHEWABLE COMPOSITION | September 2022 | June 2024 | Allow | 21 | 4 | 0 | Yes | No |
| 17884045 | FORMULATIONS OF MAZINDOL | August 2022 | July 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17793476 | DEODORANT COMPOSITION | July 2022 | July 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17792843 | STARCH FILM-FORMING COMPOSITIONS AND METHODS OF THEIR USE FOR PREPARING CAPSULE SHELLS | July 2022 | January 2026 | Allow | 42 | 1 | 1 | No | No |
| 17791324 | Joint Health Composition and Use Thereof in Healthy Mammals | July 2022 | September 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17857959 | MONOLITHIC INTRAVAGINAL RINGS COMPRISING PROGESTERONE AND METHODS OF MAKING AND USES THEREOF | July 2022 | August 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17785666 | GLUTATHIONE-CONTAINING COMPOSITION | June 2022 | May 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17782067 | CAPSULE WITH REDUCED POWDER LEAKAGE | June 2022 | December 2025 | Allow | 42 | 1 | 1 | No | No |
| 17829702 | SUSTAINED RELEASE ESTROGEN VAGINAL RING PESSARY FOR TREATMENT OF ATROPHY, CYSTITIS AND UTEROVAGINAL PROLAPSE | June 2022 | August 2023 | Allow | 14 | 2 | 1 | No | No |
| 17777566 | AN ANTIPERSPIRANT COMPOSITION | May 2022 | October 2025 | Allow | 41 | 1 | 1 | No | No |
| 17740878 | METHODS AND ARTICLES FOR ALLERGIC DESENSITIZATION VIA THE ORAL MUCOSA | May 2022 | August 2025 | Abandon | 39 | 3 | 0 | No | No |
| 17769679 | A STABLE EFFERVESCENT CO-PROCESSED EXCIPIENT COMPOSITION AND A PROCESS FOR PREPARING THE SAME | April 2022 | June 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17714769 | COMPOSITION FOR PREVENTING, INHIBITING OR TREATING INFECTION OF CORONAVIRUS | April 2022 | November 2024 | Abandon | 31 | 2 | 0 | No | No |
| 17710491 | MEDICAL DEVICE WITH A BIOCOMPATIBLE COATING | March 2022 | May 2025 | Abandon | 38 | 3 | 0 | No | No |
| 17691660 | LIQUID DRESSING | March 2022 | January 2026 | Allow | 46 | 2 | 1 | No | No |
| 17691897 | Bellows Bandage Drug Delivery System | March 2022 | May 2024 | Allow | 26 | 1 | 0 | No | No |
| 17691911 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING (1R, 5S)-1-(NAPHTHALEN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE | March 2022 | August 2024 | Abandon | 30 | 1 | 0 | No | No |
| 17685644 | COMPOSITION AND METHODS FOR GENERATING AND SUSTAINING MOLECULAR HYDROGEN (H2) IN AQUEOUS SYSTEMS | March 2022 | June 2024 | Allow | 28 | 1 | 0 | No | No |
| 17680657 | Polyurethane Based Medical Articles | February 2022 | January 2025 | Allow | 35 | 2 | 1 | No | No |
| 17637884 | MICROENCAPSULATED PROBIOTIC AND COMPOSITIONS CONTAINING THE SAME | February 2022 | May 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17676822 | PHARMACEUTICAL COMPOSITION OF LIPID NANOPARTICLE FOR DELIVERING NUCLEIC ACID DRUG CONTAINING TREHALOSE DERIVATIVE AND NOVEL STRUCTURE-MAINTAINING LIPID COMPOUND | February 2022 | June 2025 | Allow | 40 | 1 | 1 | Yes | No |
| 17636105 | COMPOSITION FOR TREATMENT OF BURN WITH SCAR REMOVAL | February 2022 | April 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17580991 | TOFACITINIB ORAL SUSTAINED RELEASE DOSAGE FORMS | January 2022 | February 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17580180 | DISSOLVABLE SOLID ARTICLE CONTAINING PRESERVATIVES | January 2022 | February 2025 | Allow | 37 | 4 | 0 | Yes | No |
| 17597601 | DOSE DUMPING RESISTANT PHARMACEUTICAL COMPOSITIONS COMPRISING VERINURAD | January 2022 | February 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17623528 | COLLAGEN POLYSACCHARIDE WOUND DRESSING | December 2021 | April 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17621319 | POULTRY FEED AND DRINKING WATER COMPOSITION COMPRISING MONOMETHYLSILANETRIOL | December 2021 | October 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17549151 | CONTROLLED RELEASE DOSAGE FORMS FOR HIGH DOSE, WATER SOLUBLE AND HYGROSCOPIC DRUG SUBSTANCES | December 2021 | March 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17545490 | FASTING MIMICKING KETOGENIC DIET TO IMPROVE IMMUNE FUNCTION AND VACCINE RESPONSE AND MINIMIZE RISK IN ADULTS AND ELDERLY | December 2021 | March 2025 | Abandon | 39 | 2 | 1 | No | No |
| 17540929 | NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY | December 2021 | June 2023 | Allow | 19 | 4 | 1 | Yes | No |
| 17539611 | SUBSTITUTED PHENYL BORONIC ACID CONTAINING POLYMERS AND METHODS OF USE | December 2021 | January 2023 | Allow | 13 | 2 | 2 | No | No |
| 17613023 | COPOLYMERS FOR STABILIZING EMULSIONS AND/OR FORMING INTERFACIAL FILMS, AND METHODS THEREOF | November 2021 | March 2025 | Allow | 40 | 1 | 1 | No | No |
| 17453468 | THERAPEUTIC PH RESPONSIVE COMPOSITIONS | November 2021 | June 2024 | Allow | 32 | 1 | 1 | No | No |
| 17516745 | Low Surfactant Personal Care Compositions | November 2021 | March 2026 | Abandon | 52 | 3 | 1 | No | Yes |
| 17607739 | 5-AMINOLEVULINIC ACID FOR THE LOCAL TREATMENT OF INFLAMMATORY BOWEL DISEASE | October 2021 | November 2024 | Abandon | 36 | 1 | 1 | No | No |
| 17512937 | COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING CEREBROVASCULAR DISEASE COMPRISING MELITTIN OR MAGNETIC IRON OXIDE NANOPARTICLE LOADED WITH MELITTIN AS EFFECTIVE COMPONENT | October 2021 | October 2025 | Abandon | 48 | 5 | 0 | No | No |
| 17507151 | BIMODAL TREATMENT METHODS AND COMPOSITIONS FOR GASTROINTESTINAL LESIONS WITH ACTIVE BLEEDING | October 2021 | June 2024 | Allow | 32 | 1 | 1 | No | No |
| 17448862 | FREEZE-DRIED ARIPIPRAZOLE FORMULATION | September 2021 | November 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17478051 | ACTIVE INGREDIENT CONTAINING STABILISED SOLID MEDICINAL FORMS AND METHODS FOR THE PRODUCTION THEREOF | September 2021 | May 2025 | Abandon | 44 | 2 | 0 | No | Yes |
| 17477644 | MULTIFUNCTIONAL (METH)ACRYLATE POLYSACCHARIDE MICROCAPSULES | September 2021 | December 2024 | Abandon | 39 | 2 | 1 | No | No |
| 17409946 | DEODORANT COMPOSITIONS WITH METAL OXIDES | August 2021 | July 2024 | Allow | 35 | 2 | 1 | Yes | No |
| 17430521 | COMPARTMENTALIZED DRUG DELIVERY DEVICES | August 2021 | October 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17397820 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTIONS | August 2021 | February 2025 | Allow | 42 | 3 | 1 | Yes | No |
| 17394446 | FLEXIBLE, POROUS, DISSOLVABLE SOLID SHEET ARTICLE CONTAINING DIRECT-ADDED MICROCAPSULES AND PROCESS FOR MAKING THE SAME | August 2021 | March 2025 | Allow | 43 | 3 | 1 | No | No |
| 17390185 | PROTEIN BASED EXCIPIENT FOR ACTIVE PHARMACEUTICAL INGREDIENTS | July 2021 | November 2025 | Allow | 51 | 6 | 1 | Yes | Yes |
| 17380509 | CONTROLLED RELEASE DOSAGE FORMS FOR HIGH DOSE, WATER SOLUBLE AND HYGROSCOPIC DRUG SUBSTANCES | July 2021 | September 2021 | Allow | 2 | 0 | 0 | No | No |
| 17373070 | SALICYLIC ACID GEL | July 2021 | February 2025 | Allow | 43 | 2 | 1 | Yes | No |
| 17367786 | Oral Care Composition Indicative Of Proper Tooth Cleaning | July 2021 | August 2023 | Abandon | 25 | 1 | 0 | No | No |
| 17362291 | PHENYLEPHRINE RESINATE PARTICLES AND USE THEREOF IN PHARMACEUTICAL FORMULATIONS | June 2021 | August 2023 | Abandon | 25 | 1 | 0 | No | No |
| 17414510 | POWDER, WOUND-COVERING MATERIAL, ADHESION PREVENTION MATERIAL, HEMOSTATIC MATERIAL, AND PRODUCTION METHOD FOR POWDER | June 2021 | May 2025 | Allow | 47 | 2 | 1 | No | No |
| 17413715 | WOUND DRESSINGS INCLUDING PVP-CITRIC ACID COPOLYMER | June 2021 | November 2025 | Abandon | 53 | 2 | 0 | Yes | No |
| 17334537 | LIQUID GRIP LOTION | May 2021 | December 2022 | Abandon | 19 | 1 | 0 | No | No |
| 17332277 | METHOD OF MAKING COMPOSITION INCLUDING ENCAPSULATED CAFFEINE | May 2021 | March 2026 | Allow | 58 | 6 | 1 | Yes | No |
| 17307755 | METHOD FOR PRODUCING SILICA PARTICLES AND THEIR USE IN COSMETIC COMPOSITIONS | May 2021 | December 2025 | Allow | 55 | 4 | 1 | No | No |
| 17286226 | COATING METHOD | April 2021 | November 2024 | Abandon | 43 | 2 | 1 | No | No |
| 17230069 | METHOD OF PREVENTING OR TREATING VIRAL INFECTIONS | April 2021 | September 2025 | Allow | 53 | 6 | 0 | Yes | No |
| 17224781 | CONTROLLED RELEASE DOSAGE FORMS FOR HIGH DOSE, WATER SOLUBLE AND HYGROSCOPIC DRUG SUBSTANCES | April 2021 | June 2021 | Allow | 3 | 0 | 0 | No | No |
| 17222343 | Anti-Obesity Agent, Anti-Dementia Agent, Deodorant, Anti-Aging Agent, Anti-Glycation Agent, Anti-Type I Allergy Agent, Hypotensive Agent, Flavor Improving Agent, Muscle Enhancing Agent, and Bone Metabolism Improving Agent | April 2021 | March 2024 | Allow | 36 | 2 | 0 | No | No |
| 17217060 | PEDIATRIC FORMULATION OF TYROSINE KINASE INHIBITORS | March 2021 | February 2024 | Abandon | 34 | 2 | 1 | No | No |
| 17301237 | Personal Care Compositions Comprising Cannabidiol and Licorice | March 2021 | March 2026 | Allow | 59 | 4 | 0 | No | Yes |
| 17216148 | Personal Care Compositions | March 2021 | December 2025 | Allow | 57 | 5 | 1 | No | No |
| 17210765 | COMPOSITIONS COMPRISING CARUM CARVI AND ROSMARINUS OFFICINALIS EXTRACTS AND METHODS OF USING SAME | March 2021 | April 2025 | Abandon | 49 | 4 | 0 | No | No |
| 17210408 | Microparticle Formulations for Delivery to the Lower and Central Respiratory Tract and Methods of Manufacture | March 2021 | December 2023 | Abandon | 33 | 2 | 0 | No | No |
| 17209288 | ANTIPERSPIRANT AND DEODORANT COMPOSITIONS FOR INCREASED SKIN LUBRICITY | March 2021 | July 2025 | Allow | 52 | 4 | 0 | No | No |
| 17202394 | COMPOSITIONS COMPRISING BENZOYL PEROXIDE FOR THE TREATMENT OF GASTROINTESTINAL DISORDER | March 2021 | January 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17193275 | POLYURETHANE UREA SOLUTIONS FOR COSMETIC COMPOSITIONS | March 2021 | February 2024 | Abandon | 36 | 2 | 0 | No | No |
| 17273492 | COMPOSITIONS AND METHODS FOR APPLICATION OVER SKIN | March 2021 | November 2024 | Allow | 44 | 3 | 1 | No | No |
| 17191090 | Topical Composition for and Method of Preventing and Treating Pressure Sores and Skin Irritation | March 2021 | October 2024 | Abandon | 43 | 3 | 0 | No | No |
| 17174389 | NAIL TREATMENT COMPOSITION | February 2021 | September 2023 | Abandon | 31 | 1 | 1 | No | No |
| 17173671 | Aloe Mint Scalp Wipes | February 2021 | November 2023 | Abandon | 33 | 2 | 0 | No | No |
| 17266048 | AN ANTIPERSPIRANT COMPOSITION | February 2021 | September 2022 | Allow | 20 | 1 | 0 | No | No |
| 17156146 | USE OF BETA-1,3-GLUCAN FOR MODULATING IMMUNE FUNCTION AND TREATING INTESTINAL INFLAMMATION | January 2021 | July 2023 | Allow | 30 | 2 | 0 | No | No |
| 17262572 | PHARMACEUTICAL METHODS AND COMPOSITIONS | January 2021 | July 2023 | Allow | 30 | 3 | 0 | No | No |
| 17260375 | PHARMACEUTICAL COMPOSITIONS WITH A CDC7 INHIBITOR | January 2021 | April 2025 | Abandon | 51 | 5 | 0 | No | No |
| 17141003 | HAIR COLORING COMPOSITIONS AND METHODS THEREOF | January 2021 | September 2023 | Allow | 32 | 3 | 0 | Yes | No |
| 17136584 | BONE REPAIR COMPOSITION AND KIT | December 2020 | July 2024 | Allow | 43 | 4 | 0 | Yes | No |
| 17253891 | Gel-In-Oil Emulsion and Transdermally Absorbed Agent | December 2020 | December 2022 | Abandon | 23 | 1 | 0 | No | No |
| 17111645 | COMPOSITIONS AND METHODS FOR MASKING THE TASTE OF DRUGS | December 2020 | November 2024 | Abandon | 47 | 4 | 1 | Yes | No |
| 17111940 | MAGNESIUM PHOSPHATE HYDROGELS | December 2020 | November 2022 | Allow | 24 | 0 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GOTFREDSON, GAREN.
With a 15.6% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 16.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner GOTFREDSON, GAREN works in Art Unit 1619 and has examined 538 patent applications in our dataset. With an allowance rate of 40.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.
Examiner GOTFREDSON, GAREN's allowance rate of 40.7% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by GOTFREDSON, GAREN receive 3.09 office actions before reaching final disposition. This places the examiner in the 88% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by GOTFREDSON, GAREN is 41 months. This places the examiner in the 20% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +32.2% benefit to allowance rate for applications examined by GOTFREDSON, GAREN. This interview benefit is in the 80% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 11.0% of applications are subsequently allowed. This success rate is in the 6% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 24.7% of cases where such amendments are filed. This entry rate is in the 33% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 60.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 50% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 52.9% of appeals filed. This is in the 23% percentile among all examiners. Of these withdrawals, 58.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 60.0% are granted (fully or in part). This grant rate is in the 64% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 1.1% of allowed cases (in the 68% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.